Mathew Martoma, the former SAC Capital Advisors employee convicted in biotech's largest insider trading scandal, is seeking a softer prison sentence for his role in the scheme. Martoma is facing recommended prison time of 15 to 20 years when he is sentenced next month, according to Bloomberg, a prospect his lawyers say is excessive considering the narrow scope of his crimes. Martoma was convicted of helping SAC reap $276 million in profits and averted losses after learning that Elan ($ELN) and Wyeth's much-hyped Alzheimer's drug bapineuzumab was about to flunk out of clinical development. News